2014
Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study
Carpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D, Gundberg CM, Insogna KL. Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3103-3111. PMID: 25029424, PMCID: PMC4154090, DOI: 10.1210/jc.2014-2017.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkaline PhosphataseBone Density Conservation AgentsChildDouble-Blind MethodErgocalciferolsFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHyperparathyroidismMaleMiddle AgedParathyroid HormonePhosphorusPlacebosProspective StudiesTreatment OutcomeVitamin DYoung AdultConceptsRenal phosphate thresholdGlomerular filtration rateBone scanSerum phosphorusFiltration rateXLH patientsEffect of paricalcitolUse of paricalcitolPlacebo-treated subjectsElevated PTH levelsSerum calcium levelsSuppression of PTHHospital research unitSerum alkaline phosphatase activityPTH levelsCreatinine levelsSecondary outcomesStandard therapyUrinary calciumPlacebo subjectsParathyroid hormoneSerum calciumAlkaline phosphatase activityD levelsSkeletal improvement
2002
Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients
1996
Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study
Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. The Journal Of Clinical Endocrinology & Metabolism 1996, 81: 3450-3454. PMID: 8855783, DOI: 10.1210/jcem.81.10.8855783.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismUntreated primary hyperparathyroidismSerum type ITumor necrosisInterleukin-6Bone resorptionSerum levelsBiochemical markersSerum deoxypyridinolineUrinary deoxypyridinolineUrinary pyridinolineBone lossCarboxyterminal telopeptideSoluble receptorClinical research center studyControl valuesNormal parathyroid functionSuccessful surgical treatmentBone-resorbing cytokinesInterleukin-1 betaType IIntact PTHParathyroid functionSurgical treatmentCenter study
1994
Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia
Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. The Journal Of Clinical Endocrinology & Metabolism 1994, 78: 1378-1383. PMID: 8200940, DOI: 10.1210/jcem.78.6.8200940.Peer-Reviewed Original ResearchConceptsHypophosphatemic ricketsFrequency of hyperparathyroidismMean iPTH valueNephrogenous cAMP excretionPathogenesis of nephrocalcinosisInitiation of therapyVitamin D preparationsGroup of patientsOnset of treatmentExaggerated secretionParathyroid statusIPTH valuesTertiary hyperparathyroidismParathyroid functionUntreated patientsOccasional complicationCAMP excretionHyperparathyroidismPhosphopenic ricketsD preparationsPatientsControl individualsRicketsIntact hormoneNocturnal rise
1988
Renal phosphate transport in humoral hypercalcemia of malignancy
Sartori L, Insogna KL, Barrett PQ. Renal phosphate transport in humoral hypercalcemia of malignancy. American Journal Of Physiology 1988, 255: f1078-f1084. PMID: 2974244, DOI: 10.1152/ajprenal.1988.255.6.f1078.Peer-Reviewed Original ResearchConceptsLeydig cell tumorHumoral hypercalcemiaOnset of hypercalcemiaTumor-bearing animalsPhosphate metabolismRenal phosphate transportCortical brush border membraneParathyroid hormoneDaily injectionsTumor transplantationCell tumorsDichloromethylene diphosphonateMicrovillus membrane vesiclesRenal cortexRenal cortical brush border membraneSodium-dependent phosphate uptakeFisher ratsAnimal modelsPersistent impairmentHypercalcemiaLow-affinity systemBrush border membraneSpecific decreaseMalignancyRats
1986
Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of Malignancy
GODSALL JW, BURTIS WJ, INSOGNA KL, BROADUS AE, STEWART AF. Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of Malignancy. 1986, 42: 705-750. PMID: 3016837, DOI: 10.1016/b978-0-12-571142-5.50021-5.BooksConceptsNephrogenous cyclic AMPCyclase-stimulating activityUcAMP excretionHumoral hypercalcemiaLocal osteolytic hypercalcemiaAdenylate cyclase-stimulating activityBone-resorbing activityCyclic AMPHPT groupNcAMP excretionNormocalcemic patientsPathophysiologic syndromeTumor extractsAnimal modelsHypercalcemiaAnimal tumorsTumorsNcAMPHHMExcretionPatientsMalignancyObserved elevationBasic proteinAMP
1980
Osteomalacia and Weakness From Excessive Antacid Ingestion
Insogna K, Bordley D, F. J, Lockwood D. Osteomalacia and Weakness From Excessive Antacid Ingestion. JAMA 1980, 244: 2544-2546. PMID: 7431592, DOI: 10.1001/jama.1980.03310220042025.Peer-Reviewed Original ResearchMeSH KeywordsAlkaline PhosphataseAluminum HydroxideCalciumFemaleHernia, HiatalHumansMiddle AgedMuscular DiseasesOsteomalaciaPhosphatesConceptsAluminum hydroxide-containing antacidElevated alkaline phosphatase levelsSerum calcium levelsAlkaline phosphatase levelsAntacid ingestionBone painPhosphate malabsorptionSevere hypophosphatemiaX-ray filmsInitial laboratory studiesPhysician awarenessUrinary phosphorusPatient's failureDietary phosphateCalcium levelsPhosphatase levelsOsteomalaciaFurther studiesHypercalciuriaHypophosphatemiaMalabsorptionPainAntacidsFailureSyndrome